Northwestern Mutual Wealth Management Co. has disclosed the acquisition of shares in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), according to a filing with the Securities and Exchange Commission (SEC). The transaction was reported in a Form 13F filing, which details the firm's holdings as of the most recent quarter.
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. The company's approved products include Onpattro (patisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) and Givlaari (givosiran) for acute hepatic porphyria.
The exact number of shares acquired and the total value of the stake were not immediately disclosed in the filing. Institutional investors often adjust their portfolios based on market conditions and company performance.
As of May 27, 2026, Alnylam's stock performance and recent developments, such as clinical trial results or regulatory decisions, could influence investor sentiment. Northwestern Mutual Wealth Management's move may reflect confidence in Alnylam's pipeline or financial outlook.
